When one compares the fast-acting 17-alpha alkylated oral version of 4-OHN (Methyl-4-hydroxynandrolone) to methyltestosterone (17-alpha-methyl-testosterone), you realize that it possesses a myotrophic (muscle building action) that is about 27 times higher than that of the well know oral AAS methyltestosterone. (Pretty cool, huh?) It also possesses androgenic properties that are over 5 times higher than methyltestosterone. However if we compare a long-chain injectable ester (4-OHN cypionate or decanoate) with prolonged release, you will find that it possesses much greater myotrophic action than testosterone cypionate…but with no androgenic properties. This is a fairly common pharmacokinetic difference between fast-acting orals and slow acting injectables. Different release patterns, alkylation or esterfication as well as metabolism dramatically alter physiological effects of the same base prosteroid.